Efficacy and Safety of Beta-glucan Supplement in Chronic Obstructive Pulmonary Disease Patients

Chulalongkorn University

Status: Not yet enrolling

Conditions: Chronic Obstructive Pulmonary Disease Patients

Treatments: Dietary Supplement: Beta-glucan supplement group; Dietary Supplement: Placebo group

Study type: Interventional

Funder types: Other

Identifiers

NCT05878834

Oh87/65

Details and patient eligibility

About

The objectives of this study are to evaluate Efficacy and safety of beta-glucan supplement in chronic obstructive pulmonary disease patients.

Full description

There are 72 patients in this study. They are randomly divided into 2 groups which are beta-glucan supplement group and placebo group. The supplement will be taken 1 capsule/day for 12 weeks. Forced expiratory volume in 1 second/Forced vital capacity, Modified Medical Research Council Dyspnea Score, Breathlessness, Cough, and Sputum Scale, 6 Minute Walk Test, Diffusing capacity for carbon monoxide, Tumor necrosis factor alpha, Interleukin-6, C-reactive protein, glutathione, aspartate transaminase, alanine transaminase, alkaline phosphatase, creatinine, and blood urea nitrogen are assessed before and after taking supplement 6 and 12 weeks.

Enrollment: 72 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age more than 18 years
• Chronic Obstructive Pulmonary Disease with Forced expiratory volume in 1 second/Forced vital capacity after receiving bronchodilator medicine more than 70%
• No exacerbation and uncontrolled disease
• 10 pack-years smoking history 10 pack-years but stop smoking more than 1 years
• Willing to participate in this study

Exclusion criteria

• Respiratory infection in 4 weeks
• Lung cancer
• Liver disease or kidney disease
• Lung surgery history
• Take kung supplement in 2 weeks
• Take warfarin, clopidogrel, aspirin, or digoxin
• Allergic to beta-glucan, broccoli, or quercetin
• Cannot use Spirometry
• Pregnancy and lactation

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

72 participants in 2 patient groups, including a placebo group

Beta-glucan supplement group

Experimental group

Description:

Beta-glucan supplement capsule composes of beta-glucan 250 mg, broccoli 75 mg, quercetin 50 mg.

Treatment:

Dietary Supplement: Beta-glucan supplement group

Placebo group

Placebo Comparator group

Description:

Placebo capsule is empty capsule.

Treatment:

Dietary Supplement: Placebo group